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effectiveness in the prevention of pneumonia due to influenza in the Colombian 
children and elderly population. METHODS: A probabilistic decision-tree model to 
simulate Influenza-Like Syndrome (ILS) burden of disease and influenza pneumo-
nia complications in Colombian population was programmed in excel. Transition 
probabilities and care costs for Colombia were obtained from a literature review 
and surveillance databases. Oseltamivir effectiveness was meta-analyzed from 
randomized trials and observational studies. Incremental cost-effectiveness ratio 
(ICER) for oseltamivir in the prevention of pneumonia complication in population 
under five years of age and older than 65 year old with ILS was estimated. Monte 
Carlo simulation with 10,000 iterations were used to estimate 95% confidence 
interval. Costs were expressed in 2013 USD. RESULTS: A total of 275,788 ILS cases 
in children and 86,675 in elderly population were estimated for 2014. Whit no 
oseltamivir would occur 75,789 and 62,817 pneumonias in children and elderly, 
respectively, and a total 22,719 deaths. Including the oseltamivir treatment at 
90% coverage would avert 33,462 pneumonias and 6639 pneumonia deaths. The 
oseltamivir cost were estimated on US$ 6,419,552, and it would be a cost-saving 
intervention in population younger than 5 years old and equal or older than 65 
years old with an ICER of US$ -953 (IC95% US$-934 to -759). CONCLUSIONS: The 
use of oseltamivir in children and elderly whit ILS appear to be a cost-saving 
strategy in Colombia, to prevent pneumonia and death complications, when it is 
administrated between 48 hours of symptoms onset.
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OBJECTIVES: To project the cost savings of introducing Fecal Microbiota Transplant 
(FMT) treatment for Clostridium difficile infection (CDI) as compared to current 
practice, by age, and three major subpopulations; hospitals, long-term care facilities 
(LTCF), and communities. METHODS: We modified our existing CDI decision ana-
lytic model to project the total cost savings of FMT as compared to current antibiotic 
treatment for CDI over five years (2015-2019), by integrating current annual trends 
in CDI, and population projections for Canada, by age, gender, and three major sub-
populations. To estimate current annual trends in CDI we conducted a systematic 
analysis of the latest provincial and federal CDI data in Canada. RESULTS: Over the 
next five years, CDI treatment with FMT is estimated to result in a potential cost 
savings of $300.4 M as compared to current practice. We projected 20,700 fewer cases 
of CDI in the FMT treatment arm, due to fewer recurrences for FMT. The recurrence 
rates for current antibiotic treatment were estimated at 25.3% and 35.9% for first 
and second recurrences, respectively. The recurrence rate for FMT was 10.4%. Over 
90% of the cost savings for FMT as compared to antibiotic treatment are for ages 60 
and over, with $127.3 M for ages 60 to 79 years, and $148.3 M for ages 80 and over. By 
subpopulation, over the next five years FMT would result in a potential cost savings 
of $216.5 M for hospital-acquired CDI (HA-CDI), and $68.7 M for community-acquired 
CDI (CA-CDI). CONCLUSIONS: Introducing FMT could result in a substantial cost 
savings over the next five years in Canada. As the Canadian population ages, and 
the numbers of CDI cases among the elderly might grow, FMT holds the promise of 
higher potential cost savings.
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OBJECTIVES: Chronic hepatitis C virus (HCV) incurs significant economic costs to 
the society. There is a paradigm shift in the treatment of hepatitis C with the intro-
duction of sofosbuvir. It is highly efficacious and safe but is an expensive treatment 
alternative to existing treatment options. The study goal is to provide an in-depth 
review of economic studies that have evaluated the cost-effectiveness of sofosbu-
vir in hepatitis C. METHODS: A comprehensive literature search was conducted 
using electronic databases such as PubMed, CINAHL, Scopus, and Cochrane Reviews. 
The search strategy included treatment-naïve as well as treatment-experienced 
patients of all genotypes. Full-text, published articles from Europe and United 
States (U.S.) were identified. Data on decision model, perspective, comparators, 
time horizon, costs, outcomes, price year, sensitivity analysis, and results were 
extracted from the reviewed studies. RESULTS: A total of 9 economic studies (5 
U.S. and 4 Europe) were identified from the literature. The comparators included 
no treatment, peginterferon+ribavirin, boceprevir, telaprevir, and simeprevir based 
regimens. Markov model utilized by all studies to simulate disease progression 
over a lifetime horizon. The cost/QALY for treatment-naïve, patients ranged from 
US$21,869-$31,152 for genotype 1 and US$78,146-$99,189 for genotype 2 and 3. The 
cost/QALY for treatment-experienced patients was US$2,277-$4290 for genotype 1 
and US$55,280-$128,324 for genotype 2 and 3. Overall, sofosbuvir was cost effec-
tive in younger patients and those with severe fibrosis. Sofosbuvir and simeprevir 
combination led to an average cost savings of US$91,590. CONCLUSIONS: Genotype 
1 HCV is the predominant genotype that is generally difficult to treat. Sofosbuvir 
is cost effective for both treatment-naïve and treatment-experienced genotype 1 
patients. For genotypes that are not predominant, decision on the use of sofosbuvir 
should be made based on the willingness-to-pay threshold values. Factors that were 
found to influence cost-effectiveness of sofosbuvir include disease severity, duration 
of treatment, and age of patients.
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with an average patient age of 63.4 (±15.8) years in the SBT group, and 81 residents 
placed 262 CVC catheter lines in patients with an average age of 62.8 (±15.2) years 
in the control group. Compared to the traditional training, the SBT was a dominant 
case with cost-saving (-$5,062, p= 0.002), and reductions of overall complications 
(3.9%, p= 0.017) and severe complications (3%, p= 0.043) per admission, resulted in 
the incremental cost-effectiveness ratios of -$1,298 (= -$5,062/3.9%) and -$1,687 (= 
-$5,062/3.0%) per 1% averted probability of overall and severe complications gained, 
respectively. The total benefit cost ratio was 10.2. Even in the first year, the SBT 
demonstrated a high return on investment (ROI) of 649% with a $4,863 net benefit 
per admission. The ROI could reach 934% and 986% in 5 years and 10 years, respec-
tively. CONCLUSIONS: Using SBT for CVC insertion is a cost-effective approach that 
can be widely implemented.
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OBJECTIVES: The aim of this analysis is to estimate the cost-effectiveness of anid-
ulafungin for the treatment of invasive candidiasis in Colombia. METHODS: We 
constructed a decision tree to determine the incremental cost-effectiveness ratio 
(ICER) of anidulafungin (200 mg on the first day, followed by 100 mg daily) compared 
to amphotericin B deoxycholate (0.7-1.0 mg daily); amphotericin B liposomal (5.0 
mg/ kg daily); caspofungin (70 mg on the first day followed by 50 mg daily) and 
fluconazole (800 mg on the first day followed by 400 mg daily) for the treatment the 
patients with invasive candidiasis. The perspective is that of the Colombian health 
system including only direct costs. All currency units are in USD $ (1 USD$ = COP 
1,971). We used a time horizon of life expectancy. A 5 % discount rate was used. The 
results were measured in quality-adjusted life year (QALY). The efficacy, safety and 
utility data were taken from the literature. Bayesian mixed treatment comparison 
method was applied for the comparison of treatments. The costs of procedures were 
obtained of ISS tariff manual of 2001 and for drugs were used current price regula-
tion and the SISMED database. Univariate and probabilistic sensitivity analyses 
were performed. RESULTS: The total expected costs per patient were: anidulafungin 
USD$ 4,685.61; amphotericin B deoxycholate USD$ 928.22; amphotericin B liposomal 
USD$ 25,569.12; caspofungin USD$ 3,368.48; fluconazole USD$ 628.39. The results for 
each alternative in terms of QALY were: anidulafungin 3.08; amphotericin B deoxy-
cholate 2.26; amphotericin B liposomal 1.90; caspofungin 2.14; fluconazole 2.46. 
The ICER per QALY of anidulafungin compared to fluconazole was USD$ 6,521.38. 
Amphotericin B deoxycholate, amphotericin B liposomal and caspofungin were 
dominated alternatives. CONCLUSIONS: Assuming as threshold for Colombia GDP 
per capita USD$ 7,609.42 anidulafungin is a cost-effective alternative for the treat-
ment of the patients with invasive candidiasis.
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OBJECTIVES: To assess the value of linezolid compared with vancomycin in the 
treatment of cSSSIs caused by MRSA from a payer perspective in the Kingdom of 
Saudi Arabia (KSA) using a two week decision analytic model. The model com-
prehensively covers direct medical costs within inpatient and outpatient settings 
related to both treatments. METHODS: Published literature and local expert opin-
ion provided clinical inputs and resource utilization data on MRSA efficacy, failure/
AE rates, length of stay (LOS), at-home parenteral administration, and outpatient 
resource use. Cost data were derived from local sources and expert feedback. 
The base case analysis assumed equal efficacy for treatment comparators within 
the 14 day length of treatment timeframe. Scenario-based sensitivity analyses 
were conducted by varying LOS data, using unit LOS costs from World Health 
Organization website, and excluding peripherally inserted central catheter (PICC) 
costs. RESULTS: The base case analysis resembled a cost-minimization analysis 
due to an equal efficacy assumption. Total drug acquisition costs were lower for 
vancomycin compared to linezolid (SAR1,885 vs. SAR7,641 respectively). However, 
the overall cost of treatment including drugs, clinical failures, complications, and 
outpatient parenteral administration were lower with linezolid (SAR14,246) than 
with vancomycin (SAR15,804) resulting in substantial cost-savings of SAR1,558 
vs. vancomycin. Linezolid provided savings due to lower outpatient medical costs 
(SAR1,548 vs. SAR7,831), specifically from outpatient parenteral administration. 
These findings were reinforced in all of the scenario sensitivity analyses, and 
linezolid was consistently the cost saving treatment alternative. CONCLUSIONS: 
Results from this analysis demonstrate the overall economic savings resulting 
from linezolid use compared with vancomycin for the treatment of MRSA cSSSI. 
Savings are seen primarily in the outpatient settings because linezolid has an oral 
formulation and does not require outpatient parenteral administration compared 
to other intravenous antibiotics.
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OBJECTIVES: Influenza disease may result in a severe disease causing hospitaliza-
tion and deaths in younger children and older adults. Early antiviral treatment 
may improve clinical outcomes. Our goal was to estimate the oseltamivir cost-
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in DCV+SOF (LE= 19.02, QALE= 12.52) compared to SOF+RBV (LE= 18.66, QALE= 12.08), 
respectively. In GT3, overall predicted costs were also lower with DCV+SOF (£315,416) 
compared to SOF+RBV (£330,737). CONCLUSIONS: In those co-infected with HIV and 
GT1 or 3 HCV, 12 weeks of treatment with DCV+SOF was predicted to be dominant 
(increased QALE with decreased costs) compared to 24 weeks of SOF+RBV.
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OBJECTIVES: The availability of effective treatment for chronic hepatitis C patients 
with advanced disease is an area of unmet medical need. The objective of this 
study was to assess the cost-effectiveness of daclatasvir+sofosbuvir (DCV+SOF) for 
the treatment of hepatitis C virus (HCV) genotypes (GT) 1, 3 and 4 in patients with 
advanced disease (METAVIR score ≥ F3) compared to standard of care. METHODS: 
DCV+SOF was compared to telaprevir+pegylated interferon-alfa+ribavirin (TVR+PR) 
and no treatment (NT) in GT1, and pegylated interferon-alfa+ribavirin (PR) and NT 
in GT3 and GT4. A published Markov model (MONARCH) was used to simulate treat-
ment in a cohort (mean age 50 years, 67% male) over a lifetime, using established 
disease transition rates, costs and health utilities. UK 2013 costs were employed, 
with costs and benefits discounted at 3.5%. Weekly treatment costs and sustained 
virologic response (SVR) rates used were: DCV: £2,038.13; SOF: £2,915.24 (DCV+SOF 
SVR: 100% GT1, GT3 and GT4); TVR: £1,866.50 (SVR: 62%); PR: £191.35 (SVR: 58% 
GT3; 45% GT4). RESULTS: In GT1, incremental costs were £15,282 and £20,798 and 
incremental QALYs were 1.95 and 4.88 compared to TVR+PR and NT, respectively. In 
GT3, incremental costs were £96,953 and £78,478, with QALY gains of 2.50 and 5.85 
for PR and NT, respectively. In GT4, incremental costs were £26,966 and £18,636, with 
QALY gains of 3.07 and 5.36 for PR and NT, respectively. Predicted ICERs were: GT1, 
£7,830 versus TVR+PR, £4,263 versus NT; GT3, £38,815 versus PR, £13,416 versus NT; 
GT4, £8,782 versus PR, £3,477 versus NT. CONCLUSIONS: At conventional UK cost 
effectiveness thresholds, treatment with DCV+SOF is estimated to be cost-effective 
compared to standard of care and no treatment in GT1 and GT4 patients with 
advanced disease. In GT3, DCV+SOF is predicted to be cost-effective compared to NT.
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OBJECTIVES: The goal of hepatitis C virus (HCV) treatment is the attainment of 
sustained virologic response (SVR). As the predominant source of infection in the 
UK is associated with high-risk behaviour among people who inject drugs (PWID), 
reducing the infected population via treatment may prevent future infections. 
This study evaluated the health economic impact of two treatment regimens, 
daclatasvir+sofosbuvir (DCV+SOF) and telaprevir+pegylated interferon-alfa+ribavirin 
(TVR+PR), in a cohort of people with high transmission risk, when accounting for 
future infections avoided. METHODS: A combined dynamic HCV transmission and 
published disease progression model (MONARCH) was populated with published UK 
data for PWID. Future costs, life years and quality-adjusted life-years (QALYs) were 
discounted at 3.5%. A prevalence parameter amongst PWID of 25% was utilised and 
results presented per 1,000 patients. The impact of treating all (25/1000) or a propor-
tion (8/1000) of patients with DCV+SOF or TVR+PR within a one-year period was 
evaluated. Published SVR rates of 95% and 59% were applied to DCV+SOF and TVR+PR, 
respectively. RESULTS: Ignoring future infections, DCV+SOF was associated with 
incremental per-patient costs of +£18,166 and incremental benefits of +1.4 QALYs and 
an incremental cost-effectiveness ratio (ICER) of £9,867 compared to TVR+PR. When 
considering reduced transmission, additional per-patient discounted cost savings of 
£8,803 and QALY gains of 1.42 were estimated, from 1,845 future infections and 328 
related long-term complications avoided over the period 2015–2065 if all patients were 
treated. The associated ICER decreased from £9,867 to £2,869. Assuming 8/1000 PWID 
were treated, the ICER decreased from £9,867 to £8,156. CONCLUSIONS: Accounting 
for the impact of SVR on future disease transmission can significantly impact cost-
effectiveness results in HCV. Factoring in the consequences of infections avoided is 
imperative when evaluating the cost-effectiveness of HCV treatment among groups 
at high risk of transmission, such as PWID.
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OBJECTIVES: To systematically review economic evaluation studies of vaccination 
programs in China. METHODS: We did a computerized search of published full 
economic evaluations of Chinese vaccination programs (published prior to March 
16, 2014) in major English and Chinese databases. RESULTS: Seventeen economic 
evaluations of 8 vaccines were identified, and Hepatitis B vaccine (29%) and 7-valent 
pneumococcal conjugate vaccine (18%) were the most studied. All studies were 
model based, but half of them used simple decision tree. 59% adopted a societal 
perspective. Eleven (65%) studies used a lifetime time horizon. 71% used the 3% 
discounting rate for base case analysis, and 24% either did not discount health 
outcomes or cost, or did not explicitly report the discounting rate. Effectiveness and 
cost data in 88% and 41%, respectively, were from literature alone. All 8 studies with 
OBJECTIVES: Hepatitis C virus (HCV) affects 3 to 4 million people in the United 
States and is a major cause of liver failure, hepatocellular carcinoma, and liver 
transplantation. Treatment of HCV has changed substantially in the last 2 years, 
with the introduction of new direct-acting antiviral therapies, which have been 
shown to reach cure rates higher than 95%. However this new class of therapies 
come at a high price, and has consequently been widely criticized. As such, it is 
important to understand the economic implications of their introduction into the 
market. The objective of the current study is to evaluate the cost-effectiveness of 
one of the most promising of these new therapies, sofosbuvir + ledipasir + riba-
virin (SOF+LDV+R), as compared to the two previous standard of care treatment 
options for treatment naïve genotype 1 infected HCV patients. METHODS: Cost-
effectiveness analysis using a Markov model of the natural disease progression 
of HCV infection and impact of treatment. We use a simulated 20 year model of a 
hypothetical cohort of 1000 patients to assess the cost-effectiveness of sofosbuvir 
+ ledipasvir + ribavirin (SOF+LDV+R), boceprevir + pegylated interferon + ribavirin 
(BOC+P+R), and telaprevir + pegylated interferon + ribavirin (TVR+P+R). RESULTS: 
Over the 20-year time horizon, no treatment resulted in 9.76 QALYs and a total 
discounted cost of $41,434, while BOC+P+R resulted in 11.06 and $88,162, TVR+P+R 
in 11.08 and $92,150 and SOF+LDV+R in 11.79 and $74,477, respectively. That is, 
our analysis showed that BOC+P+R and TVR+P+R were strongly dominated, with 
SOF+LDV+R being the most cost-effective therapy. CONCLUSIONS: Despite the high 
price of SOF+LDV+R, this new therapy not only yields higher QALYs, but actually 
costs less than the previous standard of care treatments for treatment naïve geno-
type 1 HCV patients. These results have important economic and policy implications 
for the treatment of hepatitis C.
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OBJECTIVES: Candidemia incidence in Chile has been estimated around 0.33 
(0.21–0.47) per 1,000 admissions. The aim of this analysis is to assess the cost-
effectiveness of anidulafungin compared with currently licensed antifungal agents 
in the treatment of confirmed infection of candidemia or invasive candidiasis in 
Chile. METHODS: The analysis was made from third payer perspective; the model 
timeframe was within a 6-week inpatient follow-up period with an extrapolation 
to lifetime for those surviving the 6-week period. Non-neutropenic patients were 
assumed. A tree-decision model was used to estimate potential treatment costs 
of anidulafungin vs comparator agents. Clinical success, mortality and adverse 
events rates were taken from international literature. Drug costs were taken from 
local institutional report and nephrotoxicity cost from official document, con-
sidering hemodialysis as required procedure. Comparators were: anidulafungin 
(loading dose 200mg/day, maintenance 100mg/day), caspofungin (loading dose 
70mg/day, maintenance 50mg/day), micafungin (100mg/day), fluconazole (400mg/
day), voriconazole (loading dose 6mg/kg/twice daily, maintenance 200mg twice 
daily or 4mg/kg twice daily), conventional amphotericin B [CAMB] (1 mg/kg), and 
liposomal amphotericin B [LAMB] (3mg/kg/day). It was considered an average 
patient weight of 76.4 kg (SD 25.5kg). Results are expressed as incremental cost-
effectiveness ratio (ICER) US$ per life year gained (LYG) in 2014 US$ (exchange rate 
US$1= CLP$600). RESULTS: Total costs (drugs and hospital stay) associated with the 
treatment were: CAMB US$18,664; fluconazole US$15,327; micafungin US$17,210; 
voriconazole US$17,310; anidulafungin US$17,941; caspofungin US$18,619; LAMB 
US$24,794; number of life years gained were: 6.30, 6.52, 5.55, 6.77, 7.23, 6.03 and 
5.47, respectively. Caspofungin, Amphotericin B and LAMB were dominated by 
anidulafungin; ICER of anidulafungin compared to fluconazole, micafungin and 
voriconazole was US$3,729; US$436 and US$1,371, respectively. CONCLUSIONS: 
For the analyzed scenario with threshold per life-year gained over US$3,729, anidu-
lafungin is a cost-effectiveness therapy compared to micafungin, fluconazole, 
voriconazole and generates savings compared to CAMB, caspofungin and LAMB 
for candidemia in Chile
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OBJECTIVES: Compared to infection with HCV alone, patients co-infected with HIV 
have faster disease progression, increased mortality and reduced quality adjusted 
life expectancy (QALE). The objective of this study was to compare the cost-effective-
ness of novel DAA regimens for HCV genotypes (GTs) 1 and 3 (which predominate 
in the UK) in HCV/HIV co-infected patients. METHODS: A published and validated 
lifetime HCV Markov model was used to model a cohort of patients (mean age 
50 years; 50% female) evenly distributed across fibrosis stages F0–F4, using HIV 
co-infection specific transition rates. Presented is a comparison of 12 weeks of 
daclatasvir+sofosbuvir (DCV+SOF) to 24 weeks of sofosbuvir+ribavirin (SOF+RBV) 
in treatment-naïve patients. Clinical inputs were obtained from pivotal trials: ALLY-2 
for DCV+SOF (GT1 SVR: 80/83 [96.39%]; GT3 SVR: 6/6 [100%]) and PHOTON-1/2 for 
SOF+RBV (GT1 SVR: 182/226 [80.53%]; GT3 SVR: 52/57 [91.23%]). Weekly costs were 
DCV= £2,043.15, SOF= £2,915.24 and RBV= £66.95. Published disease state costs (UK 
2013) and health utility values were used; both costs and benefits were discounted at 
3.5%. RESULTS: In GT1 patients, the model predicted that discounted life expectancy 
(LE) and QALE would increase by 0.52 and 0.69 in DCV+SOF (LE= 18.90, QALE= 12.37) 
compared to SOF+RBV (LE= 18.37, QALE= 11.68), respectively. Overall predicted costs 
were lower with DCV+SOF (£316,716) versus SOF+RBV (£334,487). In GT3 patients, 
the model predicted that discounted LE and QALE would increase by 0.36 and 0.44 
